Clinical Trial Goal
To find out:
- The highest dose of APVO436 that's safe to give
- If APVO436 is safe and works well to treat CD123+ AML that has not yet been treated
You may be able to join this trial if you:
- Are 18 years old or older
- Have CD123+ AML that has not yet been treated
- Do not have acute promyelocytic leukemia
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
APVO436 is a bispecific T-cell engager (BiTE) antibody that targets CD3 and CD123 on certain cells.
Azacitidine is a drug that blocks the growth of cancer cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Azacitidine is a drug that blocks the growth of cancer cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- APVO436 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Azacitidine – Given as IV infusions 1 time each day for 8 days
- Venetoclax – A pill that you take by mouth 1 time each day for 22 days
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has not yet approved APVO436.
Locations
Sponsors
lead: Aptevo Therapeutics
